Streetbeat News

Stock Prices

COR

Cencora's (NYSE:COR) short percent of float has fallen 14.57% since its last report, with 4.90 million shares sold short, which is 3.05% of all regular shares available for trading. It would take traders 3.24 days to cover their short positions on average. The company has less short interest than most of its peers, with an average of 7.11%.

Portfolio Pulse from Benzinga Insights

October 17, 2023 | 2:00 pm

ZTS

Zoetis's (NYSE:ZTS) short percent of float has fallen 5.0% since its last report, with 3.49 million shares sold short, which is 0.76% of all regular shares available for trading. This decrease in short interest could signal a more bullish sentiment towards the stock. Compared to its peers, Zoetis has less short interest.

Portfolio Pulse from Benzinga Insights

October 17, 2023 | 2:00 pm

TECK

Analysts have provided bullish and somewhat bullish ratings for Teck Resources (NYSE:TECK) in the last quarter, with no bearish or indifferent ratings. The average price target is $55.5, implying an upside from the current price of $39.57. This average has decreased by 0.18% from the previous average price target of $55.60.

Portfolio Pulse from Benzinga Insights

October 17, 2023 | 2:00 pm

SPY

USA Business Inventories for the month of August increased by 0.4%, beating the estimated 0.3% and the prior 0.1%.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 2:00 pm

ACI

Albertsons Companies Inc (NYSE:ACI) reported Q2 FY23 sales growth of 2% YoY to $18.29 billion, slightly above the analyst consensus estimate. The growth was driven by a 2.9% increase in identical sales, a 19% increase in digital sales, and retail price inflation. However, the gross margin rate contracted 30 basis points to 27.6% due to strong growth in pharmacy operations and increases in shrink. The company's Board declared a cash dividend for Q3 of fiscal 2023 of $0.12 per share. ACI shares are trading lower by 0.22% at $22.45.

Portfolio Pulse from Shivani Kumaresan

October 17, 2023 | 1:59 pm

GS

Goldman Sachs CEO has stated that the impact of tightening will be more evident in the next two to four quarters.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 1:57 pm

MRNA

PFE

Moderna Inc's shares continue to trade lower following Pfizer Inc's warning about reduced Covid-19 product demand. Pfizer slashed its full-year 2023 sales outlook from $67 billion-$70 billion to $58 billion-$61 billion, causing shares of several Covid vaccine makers, including Moderna, to slide. Despite this, Moderna reaffirmed its $6 billion-$8 billion forecast for Covid vaccine sales for the year.

Portfolio Pulse from Adam Eckert

October 17, 2023 | 1:52 pm

ASMB

GILD

Gilead Sciences Inc and Assembly Biosciences Inc have entered into a 12-year partnership to advance the research and development of novel antiviral therapies. Assembly Bio will receive $100 million from Gilead, which has also agreed to purchase up to 29.9% of Assembly Bio's outstanding voting stock at a premium. Gilead may opt-in to obtain exclusive rights for each of Assembly Bio's current and future programs. This transaction is expected to reduce Gilead's GAAP and non-GAAP 2023 EPS by seven cents.

Portfolio Pulse from Vandana Singh

October 17, 2023 | 1:51 pm

EVLO

Evelo Biosciences Inc (NASDAQ:EVLO) announced that it did not achieve the primary endpoint in its Phase 2 clinical study with EDP2939 in moderate psoriasis. The company will cease the development of EDP2939 and is considering strategic alternatives, including partnering EDP1815 and the SINTAX platform. Following the news, EVLO shares dropped 48.3%.

Portfolio Pulse from Vandana Singh

October 17, 2023 | 1:49 pm

TPST

Trading of Tempest Therapeutics shares has resumed.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 1:49 pm